期刊文献+

糖胺聚糖方案治疗老年急性髓系白血病的疗效及预后影响因素 被引量:6

下载PDF
导出
摘要 目的探讨糖胺聚糖(CAG)方案治疗老年急性髓系白血病(AML)的临床效果及其预后影响因素。方法选择2005年3月至2014年3月确诊的52例老年AML患者,随机分为CAG组和对照组,CAG组采用阿糖胞苷(Ara-C)、阿柔比星及重组人粒细胞集落刺激因子针(G-CSF)联合治疗,对照组采用常规治疗方案进行治疗,对两组患者治疗后的临床缓解率及不良反应发生情况进行对比分析,同时对CAG组患者治疗预后影响因素如性别、年龄、病因等进行对比分析。结果 CAG组总有效率(65.4%)高于对照组(42.3%),CAG组治疗后骨髓恢复时间、平均输注浓缩红细胞数及平均输注单采血小板量均明显低于对照组(P<0.05);统计学分析发现,年龄超过70岁、继发性白血病患者、白细胞计数(WBC)≥100×109/L、血小板(PLT)<20×109/L、骨髓原始细胞比例≥0.5的患者其CAG方案治疗后的缓解率低于其他患者(P<0.05)。结论与对照组相比,CAG方案治疗组患者缓解率高、骨髓恢复时间短、输血量少、安全性高。影响CAG方案治疗老年AML预后的相关因素主要有年龄、病因、WBC水平、PLT水平及骨髓原始细胞比例等。
作者 冀晓红
机构地区 商洛市中心医院
出处 《中国老年学杂志》 CAS CSCD 北大核心 2015年第2期374-375,共2页 Chinese Journal of Gerontology
  • 相关文献

参考文献5

  • 1张冰,张东华.老年急性髓细胞白血病的治疗策略与进展[J].医学综述,2011,17(6):883-886. 被引量:8
  • 2谢瑜,谭琳,聂波,曾云.CAG方案治疗老年急性髓系白血病疗效观察[J].中国医药导报,2011,8(2):151-152. 被引量:8
  • 3Kumi Oshima,Wataru Takahashi,Yuki Asano-Mori,Koji Izutsu,Tsuyoshi Takahashi,Yukihiro Arai,Yasunori Nakagawa,Kensuke Usuki,Mineo Kurokawa,Kenshi Suzuki,Kinuko Mitani,Yoshinobu Kanda.Intensive chemotherapy for elderly patients with acute myelogeneous leukemia: a propensity score analysis by the Japan Hematology and Oncology Clinical Study Group (J-HOCS)[J]. Annals of Hematology . 2012 (10)
  • 4Betul Oran,Daniel J. Weisdorf.Survival for older patients with acute myeloid leukemia: a population-based study. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL . 2012
  • 5Guoqing Wei,Wanmao Ni,Jen-wei Chiao,Zhen Cai,He Huang,Delong Liu.A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. Journal of Hematology & Oncology . 2011

二级参考文献26

  • 1ChesonBD,BennettJM,KopeckyKJ,周学慧,肖志坚.国际工作组关于急性髓系白血病治疗试验的诊断、疗效标准的标准化、治疗结局和报告标准的修订建议[J].白血病.淋巴瘤,2004,13(4):246-250. 被引量:31
  • 2吴小津,吴德沛,孙爱宁,唐晓文,付铮铮,马骁.预激方案诱导治疗老年性急性髓系白血病的疗效观察[J].中华内科杂志,2004,43(12):936-937. 被引量:29
  • 3Tabata M, Yoshida M, Izumi T, et al. Retrospective analysis of elderly patients or >/60 years of age with acute leukemia [J]. Rinsho Ketsueki2007, 39(3):176-184.
  • 4Bai A, Kojima H, Hori M, et al. Primary with G-CSF effectively enhances low dose Ara-c induced in vivo apoptosis in myeloid leukemia cells [J]. Exp Hematol,1992,27(2):259-285.
  • 5Akashi K, Eto T, Shibuya T, et al. Aclarubicin induces differentiation of leukemia progenitors in myelodysplastic syndrome cooperating with granulocyte colony-stimulating factor [J]. Leuk Res,2000,24(3):243-248.
  • 6Saito K, Nakamura Y, Aoyagi M, et al. Low dose cytarabine and aclarubicin in combination with granuloeyte colony stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blast sin transformation [J]. Int J Hematol,2000,71(3):238-244.
  • 7Laubach J, Rao AV. Current and emerging strategies for the man- agement of acute myeloid leukemia in the elderly [ J ]. Oncologist, 2008,13(10) :1097-1108.
  • 8Sti~walt DL, Kopecky K J, Meshinchi S, et al. FLT3, RAS, and 33?53 mutations in elderly patients with acute myeloid leukemia [ J]. Blood ,2001,97 ( 11 ) :3589-3595.
  • 9Etienne A, Esterni B, Charbonnier A, et al. Comorbidity is an inde- pendent predictor of complete remission in elderly patients receiv- ing induction chemotherapy for acute myeloid leukemia[ J]. Canc- er,2007,109(7) :1376-1383.
  • 10Appelbaum FR, Gundacker H, Head DR, et al. Age and acute mye- loid leukemia[ J ]. Blood,2006,107 (9) :3481-3485.

共引文献14

同被引文献56

引证文献6

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部